US 12,226,375 B1
Method of treatment and selection of patients benefiting from agomelatine based on EEG measurements
Amit Etkin, Los Altos, CA (US); Wei Wu, Los Altos, CA (US); Adam Savitz, Los Altos, CA (US); Joshua Jordan, Los Altos, CA (US); Maimon Rose, Los Altos, CA (US); and Akshay Sujatha Ravindran, Los Altos, CA (US)
Assigned to ALTO NEUROSCIENCE, INC., Mountain View, CA (US)
Filed by Alto Neuroscience, Inc., Los Altos, CA (US)
Filed on May 21, 2024, as Appl. No. 18/670,566.
Claims priority of provisional application 63/518,742, filed on Aug. 10, 2023.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/165 (2006.01); A61K 45/06 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/165 (2013.01) [A61K 45/06 (2013.01); A61P 25/24 (2018.01)] 17 Claims
OG exemplary drawing
 
1. A method of treating major depressive disorder in a patient,
where the patient is being treated with an antidepressant other than agomelatine but has failed to adequately respond to the antidepressant, the method comprising:
(a) measuring EEG sample entropy in the 30-40 Hz frequency range in the patient; and
(b) upon the patient being determined to be responsive to agomelatine based on having high EEG sample entropy, administering to the patient an effective amount of (i) agomelatine or a pharmaceutically acceptable salt thereof and (ii) the antidepressant.